Modification at the lipophilic domain of RXR agonists differentially influences activation of RXR heterodimers

Fuminori Ohsawa, Ken Ichi Morishita, Shoya Yamada, Makoto Makishima, Hiroki Kakuta

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

RXR permissive heterodimers are reported to be activated differently depending upon the chemical structure of RXR agonists, but the relationship of agonist structure to differential heterodimer activation has not been explored in detail. In this study, we performed systematic conversion of the alkoxy side chain of 5a (6-[ethyl-(3-isopropoxy-4-isopropylphenyl)amino]nicotinic acid, NEt-3IP) and evaluated the RXR-, PPAR/RXR-, and LXR/RXR-agonist activities of the products. The cyclopropylmethoxy analogue (5c) showed similar RXR- and LXR/RXR-agonistic activities to the benzyloxy analogue (5i) and n-propoxy analogue (5k) but exhibited more potent PPAR/RXR-agonistic activity than 5i or 5k. Differential modulation of RXR heterodimer-activating ability by conversion of the alkoxy group located in the lipophilic domain of the RXR-agonist common structure is expected be a useful approach in the design of new RXR agonists for the treatment of hyperlipidemia or type 2 diabetes.

Original languageEnglish
Pages (from-to)521-525
Number of pages5
JournalACS Medicinal Chemistry Letters
Volume1
Issue number9
DOIs
Publication statusPublished - Dec 9 2010

Fingerprint

Peroxisome Proliferator-Activated Receptors
Chemical activation
Niacin
Medical problems
Hyperlipidemias
Type 2 Diabetes Mellitus
Modulation
alkoxyl radical

Keywords

  • heterodimer activation
  • LXR
  • permissive heterodimers
  • PPAR
  • reporter gene assay
  • RXR agonists

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Biochemistry

Cite this

Modification at the lipophilic domain of RXR agonists differentially influences activation of RXR heterodimers. / Ohsawa, Fuminori; Morishita, Ken Ichi; Yamada, Shoya; Makishima, Makoto; Kakuta, Hiroki.

In: ACS Medicinal Chemistry Letters, Vol. 1, No. 9, 09.12.2010, p. 521-525.

Research output: Contribution to journalArticle

Ohsawa, Fuminori ; Morishita, Ken Ichi ; Yamada, Shoya ; Makishima, Makoto ; Kakuta, Hiroki. / Modification at the lipophilic domain of RXR agonists differentially influences activation of RXR heterodimers. In: ACS Medicinal Chemistry Letters. 2010 ; Vol. 1, No. 9. pp. 521-525.
@article{1c5d01d75cae4ffaa6621c005ae2a538,
title = "Modification at the lipophilic domain of RXR agonists differentially influences activation of RXR heterodimers",
abstract = "RXR permissive heterodimers are reported to be activated differently depending upon the chemical structure of RXR agonists, but the relationship of agonist structure to differential heterodimer activation has not been explored in detail. In this study, we performed systematic conversion of the alkoxy side chain of 5a (6-[ethyl-(3-isopropoxy-4-isopropylphenyl)amino]nicotinic acid, NEt-3IP) and evaluated the RXR-, PPAR/RXR-, and LXR/RXR-agonist activities of the products. The cyclopropylmethoxy analogue (5c) showed similar RXR- and LXR/RXR-agonistic activities to the benzyloxy analogue (5i) and n-propoxy analogue (5k) but exhibited more potent PPAR/RXR-agonistic activity than 5i or 5k. Differential modulation of RXR heterodimer-activating ability by conversion of the alkoxy group located in the lipophilic domain of the RXR-agonist common structure is expected be a useful approach in the design of new RXR agonists for the treatment of hyperlipidemia or type 2 diabetes.",
keywords = "heterodimer activation, LXR, permissive heterodimers, PPAR, reporter gene assay, RXR agonists",
author = "Fuminori Ohsawa and Morishita, {Ken Ichi} and Shoya Yamada and Makoto Makishima and Hiroki Kakuta",
year = "2010",
month = "12",
day = "9",
doi = "10.1021/ml100184k",
language = "English",
volume = "1",
pages = "521--525",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Modification at the lipophilic domain of RXR agonists differentially influences activation of RXR heterodimers

AU - Ohsawa, Fuminori

AU - Morishita, Ken Ichi

AU - Yamada, Shoya

AU - Makishima, Makoto

AU - Kakuta, Hiroki

PY - 2010/12/9

Y1 - 2010/12/9

N2 - RXR permissive heterodimers are reported to be activated differently depending upon the chemical structure of RXR agonists, but the relationship of agonist structure to differential heterodimer activation has not been explored in detail. In this study, we performed systematic conversion of the alkoxy side chain of 5a (6-[ethyl-(3-isopropoxy-4-isopropylphenyl)amino]nicotinic acid, NEt-3IP) and evaluated the RXR-, PPAR/RXR-, and LXR/RXR-agonist activities of the products. The cyclopropylmethoxy analogue (5c) showed similar RXR- and LXR/RXR-agonistic activities to the benzyloxy analogue (5i) and n-propoxy analogue (5k) but exhibited more potent PPAR/RXR-agonistic activity than 5i or 5k. Differential modulation of RXR heterodimer-activating ability by conversion of the alkoxy group located in the lipophilic domain of the RXR-agonist common structure is expected be a useful approach in the design of new RXR agonists for the treatment of hyperlipidemia or type 2 diabetes.

AB - RXR permissive heterodimers are reported to be activated differently depending upon the chemical structure of RXR agonists, but the relationship of agonist structure to differential heterodimer activation has not been explored in detail. In this study, we performed systematic conversion of the alkoxy side chain of 5a (6-[ethyl-(3-isopropoxy-4-isopropylphenyl)amino]nicotinic acid, NEt-3IP) and evaluated the RXR-, PPAR/RXR-, and LXR/RXR-agonist activities of the products. The cyclopropylmethoxy analogue (5c) showed similar RXR- and LXR/RXR-agonistic activities to the benzyloxy analogue (5i) and n-propoxy analogue (5k) but exhibited more potent PPAR/RXR-agonistic activity than 5i or 5k. Differential modulation of RXR heterodimer-activating ability by conversion of the alkoxy group located in the lipophilic domain of the RXR-agonist common structure is expected be a useful approach in the design of new RXR agonists for the treatment of hyperlipidemia or type 2 diabetes.

KW - heterodimer activation

KW - LXR

KW - permissive heterodimers

KW - PPAR

KW - reporter gene assay

KW - RXR agonists

UR - http://www.scopus.com/inward/record.url?scp=78650207455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650207455&partnerID=8YFLogxK

U2 - 10.1021/ml100184k

DO - 10.1021/ml100184k

M3 - Article

AN - SCOPUS:78650207455

VL - 1

SP - 521

EP - 525

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 9

ER -